Use of Intravascular Ultrasound to Compare Effects of Different Strategies of Lipid-Lowering Therapy on Plaque Volume and Composition in Patients With Coronary Artery Disease
Autor: | Karl R. Karsch, Michael Gross, Dirk Hausmann, Jörg Kreuzer, Stephan Beckmann, Dietmar H. Koschyk, Michael Schartl, Wolfgang Bocksch, Wolfram Voelker |
---|---|
Rok vydání: | 2001 |
Předmět: |
medicine.medical_specialty
Patient Dropouts Arteriosclerosis Atorvastatin medicine.medical_treatment Cholestyramine Resin Coronary Disease Coronary artery disease chemistry.chemical_compound Physiology (medical) Internal medicine Intravascular ultrasound medicine Humans Pyrroles Triglycerides Ultrasonography Interventional Venous Thrombosis Chemotherapy medicine.diagnostic_test business.industry Cholesterol Vascular disease Anticholesteremic Agents Cholesterol HDL Exanthema medicine.disease Arthralgia Surgery Clinical trial Butyrates Treatment Outcome chemistry Heptanoic Acids Creatinine Cardiology Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business medicine.drug |
Zdroj: | Circulation. 104:387-392 |
ISSN: | 1524-4539 0009-7322 |
DOI: | 10.1161/hc2901.093188 |
Popis: | Background We studied whether lipid-lowering therapy with atorvastatin (target LDL cholesterol [LDL-C] Methods and Results This study was a 12-month, open-label, randomized, multicenter trial, which used serial 3D intracoronary ultrasound to calculate plaque volume and plaque echogenicity. After transcatheter therapy, 131 patients were randomized (atorvastatin n=65, usual care n=66). The target plaque had to be a minor lesion (ie, a diameter stenosis of 3 , atorvastatin 1.2±30.4 mm 3 ; P =0.191). The hyperechogenicity index of the plaque increased to a larger extent for the atorvastatin group than for the usual care group, with a significant treatment effect for the percent change (atorvastatin 42.2%, usual care 10.1%; P =0.021). Conclusions One year of lipid-lowering therapy to |
Databáze: | OpenAIRE |
Externí odkaz: |